Targeting cell cycle and hormone receptor pathways in cancer. - Wikidata - awgldk - TriplyDB

Targeting cell cycle and hormone receptor pathways in cancer.

Targeting cell cycle and hormone receptor pathways in cancer.

http://www.wikidata.org/entity/Q37502364

about

The other side of the coin: the tumor-suppressive aspect of oncogenes and the oncogenic aspect of tumor-suppressive genes, such as those along the CCND-CDK4/6-RB axis Targeting the adaptive molecular landscape of castration-resistant prostate cancer Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines.Integrative clinical genomics of advanced prostate cancer.CDK4/6 Inhibitors in Cancer Therapy: A Novel Treatement Strategy for Bladder Cancer.The efficacy of the cyclin-dependent kinase 4/6 inhibitor in endometrial cancer Palbociclib (PD-0332991), a selective CDK4/6 inhibitor, restricts tumour growth in preclinical models of hepatocellular carcinoma.CDK4/6 and IGF1 receptor inhibitors synergize to suppress the growth of p16INK4A-deficient pancreatic cancers.The history and future of targeting cyclin-dependent kinases in cancer therapy.Beyond the androgen receptor: new approaches to treating metastatic prostate cancer. Report of the 2013 Prouts Neck Prostate Cancer Meeting Novel actions of next-generation taxanes benefit advanced stages of prostate cancer.RelA-Induced Interferon Response Negatively Regulates Proliferation Consequence of the tumor-associated conversion to cyclin D1b The HSP90 inhibitor 17-PAG effectively inhibits the proliferation and migration of androgen-independent prostate cancer cells Advanced neuroendocrine prostate tumors regress to stemness Androgen receptor is a potential novel prognostic marker and oncogenic target in osteosarcoma with dependence on CDK11.Cytotoxic chemotherapy in the contemporary management of metastatic castration-resistant prostate cancer (mCRPC).Palbociclib: first global approval.RB Loss Promotes Prostate Cancer Metastasis.A Novel Class of Hsp90 C-Terminal Modulators Have Pre-Clinical Efficacy in Prostate Tumor Cells Without Induction of a Heat Shock Response.Inhibition of DNA damage repair by the CDK4/6 inhibitor palbociclib delays irradiated intracranial atypical teratoid rhabdoid tumor and glioblastoma xenograft regrowth.Palbociclib has antitumour effects on Pten-deficient endometrial neoplasias.Intensified antineoplastic effect by combining an HDAC-inhibitor, an mTOR-inhibitor and low dosed interferon alpha in prostate cancer cells.Capsaicin: a novel radio-sensitizing agent for prostate cancer.The retinoblastoma tumor suppressor modulates DNA repair and radioresponsiveness.The Strange Case of CDK4/6 Inhibitors: Mechanisms, Resistance, and Combination Strategies.Cell cycle-coupled expansion of AR activity promotes cancer progression.CDK4/6 inhibition is more active against the glioblastoma proneural subtype.Differential impact of RB status on E2F1 reprogramming in human cancer.Inhibiting CDK in Cancer Therapy: Current Evidence and Future Directions.MAPK reliance via acquired CDK4/6 inhibitor resistance in cancer.Synthesis and pharmacological evaluation of novel epidermal growth factor receptor inhibitors against prostate tumor cells A patient-derived explant (PDE) model of hormone-dependent cancer

P2860

Q26865888-8C55D8A8-B39C-48B4-BCA1-7A52CF587876 Q27022821-3DB397E0-4740-4DCF-AD8B-BEF966CEC44E Q27852814-9298260E-3B55-4028-960B-4FF90B9F5B5A Q27853170-D9995A74-6DC5-4EC9-B178-61AB85590AD6 Q33614544-7DD65D01-B035-4832-B6E9-1A1E90AE744E Q33638023-F44C23FF-EE1F-4976-AFC7-D819C057E427 Q33907588-884F8222-183F-4020-BA32-671064C1274C Q34004428-EDD33488-ACE9-4F88-8A77-69FC18F529C9 Q34460347-16BE547C-2428-48A7-9B0C-044D8EE6ED61 Q34617627-D0A210ED-6F74-4BDB-9CDD-37107EA2FE42 Q35099127-E5939645-A513-41B2-90B5-F2B78F1A753B Q35804406-4E1FD7CA-ED43-4F0D-898C-3FCB981F0F37 Q35822584-B354A13F-72F8-4F82-B8D9-727FE43B5C23 Q36309425-319AF24E-5E53-4F4A-8916-A2560BA9F810 Q36332128-BF95712E-4467-4F96-8DF5-971999A6FA61 Q37682137-A00FCB71-9E48-4CDE-B99B-C2B9B1F8B5B2 Q38232184-16C20EEE-F297-4C30-AA94-4053F83B6721 Q38384741-65A819B6-A859-4649-A1EF-CB85E201D182 Q38727367-63A3E91D-0198-4C3D-8E44-4C794E1C3647 Q38740513-AC2ACC4F-5DF0-4CA1-AEEB-FAC37375835C Q38760366-D45C8662-408C-44B4-B05F-8D004B0B901D Q38871799-A125DAE9-3201-4CB8-B0C1-DE01D890372B Q38895320-CD92D19D-9C30-4F53-838F-638F08A4B45F Q38948728-2E7FF12C-8278-412A-8891-25514AD5B45C Q38962238-9B20CC0A-1110-476B-822A-43A2DAA43187 Q39183079-D9C5188C-70CC-4AAA-8462-CA68006B378A Q40565537-3830F960-EE74-482B-9FC3-B0645012DF17 Q41548769-63F9154B-86A7-455D-9B76-85FF36170C93 Q46068832-FEA4ADFE-1591-41D9-9F15-C1694F4200EA Q47316489-7C7B2B1F-7065-47C5-A91F-970FA49AD22F Q53685801-77773C9D-896C-4E5E-8A95-99D6D9E67F32 Q58572503-D61E2927-C307-4E1C-B743-83A334D1CA71 Q58772979-F4FD0A9F-D8C4-4FA9-A82B-031B7CC59910

P2860

Targeting cell cycle and hormone receptor pathways in cancer.

http://www.wikidata.org/entity/Q37502364

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 27 May 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Targeting cell cycle and hormone receptor pathways in cancer.

@en

Targeting cell cycle and hormone receptor pathways in cancer.

@nl

type

label

Targeting cell cycle and hormone receptor pathways in cancer.

@en

Targeting cell cycle and hormone receptor pathways in cancer.

@nl

prefLabel

Targeting cell cycle and hormone receptor pathways in cancer.

@en

Targeting cell cycle and hormone receptor pathways in cancer.

@nl

P1433

Q37502364-429B8EA7-DAA3-404B-9012-877734AEEF71

P1476

Q37502364-E60B004F-B916-481E-9832-9FBF35B0CB4A

P2093

Q37502364-0022B9D1-5F77-471A-848A-ABB6F0567B1F

Q37502364-03FB4DAA-1706-40D7-AA17-F17BCB0A4A06

Q37502364-21C4120B-4992-418E-BA7B-13958E7045B5

Q37502364-41EDF087-30F5-4C1A-9B21-58363B3F312E

Q37502364-5D3F59DD-00C3-4252-BD26-CE4E1A98C02C

Q37502364-86735A09-9B73-4E5B-89C6-A914EBF51015

Q37502364-9EE48D76-1C1C-47AE-BCEC-FA14B2F06367

Q37502364-A2E0FFAA-4CFE-4845-AB69-A1A50DE8DCB9

Q37502364-CC842234-D546-4C50-B201-7FF5581BB80D

Q37502364-DEF584B4-B12D-4349-81EE-D07EB8FA30EB

P2860

Q37502364-044FA983-FA38-4E15-9901-06EAE5D3404B

Q37502364-05A66F3C-C542-40CF-B75D-82D6D71429E3

Q37502364-09A76A24-0DED-42A2-BF2D-16AC77746C9E

Q37502364-110F7004-7821-44B8-8045-54E1DC06EC76

Q37502364-1A8D104C-E9CC-49E5-866D-1E84B8FFABD7

Q37502364-1D509AF4-23A9-4F25-AFF2-13651A5E8AB5

Q37502364-22913BCA-B781-4191-88A8-007829832DAA

Q37502364-2784DD94-E02E-4227-8832-A71B34DD408B

Q37502364-3094738D-9E60-46EB-88BA-C285169CAF43

Q37502364-32FA6F5D-34AB-4302-A990-088D2FD15A56

P2888

Q37502364-40B4C8BA-973D-426A-8A64-66273485F22E

P304

Q37502364-4D373B31-005A-48A4-94C4-F1CD10C3F09D

P31

Q37502364-96923288-6972-4402-B98B-E68253DC59DA

P356

Q37502364-E398E30C-2AE6-4787-8489-740814FF8C1C

P407

Q37502364-6354BA70-FF85-4F6B-9329-60ED77895D64

P433

Q37502364-3B9EDB54-012E-497C-B117-A972E7D18732

P478

Q37502364-495FF24D-BC92-4D7E-A7CA-73852D62AD50

P50

Q37502364-3AE502F2-48B2-4DC4-A198-5BB960222AE5

Q37502364-5F130AA6-0BEC-4519-91D6-D8633BEA9B3C

Q37502364-65D7DC2E-A20D-4727-9D6B-555FA170EC34

P577

Q37502364-60B30339-553D-4FA5-B331-93BACDAD7770

P5875

Q37502364-E48628D5-70A5-492E-9F5C-3C9D20B15069

P698

Q37502364-0C9D69C3-E09A-455C-9A6B-61F37435B5C8

P932

Q37502364-8B557BE2-6E55-4C29-B42B-E4822F19AA4E

P356

P1433

P1476

Targeting cell cycle and hormone receptor pathways in cancer

@en

P2093

A K McClendon

http://www.w3.org/2001/XMLSchema#string

C D Lallas

http://www.w3.org/2001/XMLSchema#string

C E S Comstock

http://www.w3.org/2001/XMLSchema#string

E J Trabulsi

http://www.w3.org/2001/XMLSchema#string

J F Goodwin

http://www.w3.org/2001/XMLSchema#string

J R Brody

http://www.w3.org/2001/XMLSchema#string

L G Gomella

http://www.w3.org/2001/XMLSchema#string

M A Augello

http://www.w3.org/2001/XMLSchema#string

M J Schiewer

http://www.w3.org/2001/XMLSchema#string

P A McCue

http://www.w3.org/2001/XMLSchema#string

P2860

PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro

A systematic screen for CDK4/6 substrates links FOXM1 phosphorylation to senescence suppression in cancer cells

Crystal structure of human CDK4 in complex with a D-type cyclin

Crystal structure of the complex of the cyclin D-dependent kinase Cdk6 bound to the cell-cycle inhibitor p19INK4d

Pharmacologic inhibition of cyclin-dependent kinases 4 and 6 arrests the growth of glioblastoma multiforme intracranial xenografts.

Therapeutic CDK4/6 inhibition in breast cancer: key mechanisms of response and failure.

A synthetic lethal interaction between K-Ras oncogenes and Cdk4 unveils a therapeutic strategy for non-small cell lung carcinoma.

Expression of p16 and retinoblastoma determines response to CDK4/6 inhibition in ovarian cancer.

Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma.

Crystal structure of cyclin-dependent kinase 2

P2888

P304

5481-5491

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/ONC.2013.83

http://www.w3.org/2001/XMLSchema#string

P407

P433

48

http://www.w3.org/2001/XMLSchema#string

P478

32

http://www.w3.org/2001/XMLSchema#string

P50

Karen E Knudsen

Margaret M Centenera

P577

2013-05-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

236939795

http://www.w3.org/2001/XMLSchema#string

P698

23708653

http://www.w3.org/2001/XMLSchema#string

P932

3898261

http://www.w3.org/2001/XMLSchema#string